Radiotherapy for Cancer of the Pancreas T. Manabe 1 , T. Tobe 1 , M. Abe 2 , M. Takahashi 2 , Y. Shibamoto 2 1The First Department of Surgery, Faculty of NTedicine, Kyoto University 2Department of Radiology, Faculty of Medicine, Kyoto University pp.1207-1213
Published Date 1984/11/25
DOI https://doi.org/10.11477/mf.1403109556
  • Abstract
  • Look Inside

 Twelve patients with cancer of the pancreas underwent intraoperative radiation (n=5) or external radiation (n=7) therapy. Of the five patients with intraoperative radiotherapy, three patients who had pancreatectomy received a dose of 2,500~3,000 rad on the 6~10 MeⅤ Betatron (Fig. 3). One patient developed radiation pancreatitis and died 0.7 month after the surgery. One died of hepatic metastasis 8.5 months after the surgery, however, recurrence was not found in the radiation field. The other one is alive for 1.5 months after the surgery. For two patients with unresectable cancer, a dose of 2,500~3,000 rad using 13~16 MeⅤ Betatron was irradiated intraoperatively. These two patients are alive for 0.5 and 1.0 months after the surgery (Table 1).

 Seven patients were treated with external beam radiation with a dose of 2,800~5,000 rad using 10 MeⅤ lineac x-ray (Fig. 5). Of two patients with pancreatectomy, one died of recurrent disease 13.4 months after the surgery and one is alive for 9.5 months after the surgery. In five patients with distant metastases to the liver, lung or peritoneal dissemination, external beam irradiation did not produce any prolongation of their survivals, however, remarkable effects on performance status were obtained (Table 2).

Copyright © 1984, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院